CD34+CD19-CD22+ B-cell progenitors might underlie phenotypic escape in patients treated with CD19-directed therapies

CD19-directed immunotherapies have revolutionized the treatment of advanced B-ALL. Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. B-ALL patients successfully treated with CD19-directed T-cells eventually relapse, which coupled with the early onset of CD...

Ամբողջական նկարագրություն

Մատենագիտական մանրամասներ
Հիմնական հեղինակներ:	Bueno, C, Barrena, S, Bataller, A, Ortiz-Maldonado, V, Elliott, N, O'Byrne, S, Wang, G, Rovira, M, Gutierrez-Agüera, F, Trincado, JL, Gonzalez, M, Morgades, M, Sorigué, M, Barcena, P, Zanetti, SR, Torrebadell, M, Vega-García, N, Rives, S, Mallo, M, Sole, F, Mead, AJ, Roberts, I, Thongjuea, S, Psaila, B, Juan, M, Delgado, J, Urbano-Ispizua, Á, Ribera, J-M, Orfao, A, Roy, A, Menéndez, P
Ձևաչափ:	Journal article
Լեզու:	English
Հրապարակվել է:	American Society of Hematology 2022

CD34+CD19-CD22+ B-cell progenitors might underlie phenotypic escape in patients treated with CD19-directed therapies

Նմանատիպ նյութեր